“I recognize many of you thought I would announce my retirement, but if I ever were to announce my retirement, it probably wouldn’t be in a downtown Los Angeles hotel with this pretty ugly carpet.”
It was March 7, 2016, when tennis superstar Maria Sharapova uttered those words before countless sports reporters. The carpet upon which the Russian stood was, far from aesthetically pleasing – unless one appreciates large red ornaments on a yellow background.
Just a day prior, the athlete’s team had called a press conference, promising a “Major Announcement.” Speculation immediately ran rampant among reporters and tennis fans as to whether the five-time Grand Slam champion would announce her retirement. But things unfolded differently.
A Doping Admission Shocks the Tennis World
What ultimately came, however, sent shockwaves through the tennis world. Sharapova, one of the most successful players of her time, announced she had failed a doping test.
“I received a letter from the ITF (International Tennis Federation) that I tested positive for a prohibited substance, meldonium, at the Australian Open,” Sharapova said in her statement. “I take full responsibility.”
The Russian tested positive for meldonium, a medication that had only been added to the World Anti-Doping Agency’s list of prohibited substances on January 1, 2016, during the year’s first Grand Slam tournament.
Long-Term Use of the Medication
“Over the past ten years, my doctor has been prescribing me a medicine called Mildronat. A few days ago, after receiving the letter from the ITF, I found out it also has another name, which I didn’t know, meldonium,” Sharapova explained.
She continued, “It’s exceptionally important for you to understand that this medicine was not on WADA’s banned list for ten years and I have been taking the medicine for ten years legally. But on January 1st, the rules changed and meldonium became a prohibited substance, which I did not know.”
Meldonium, a blood flow-enhancing drug that promotes oxygen uptake and, endurance, had reportedly been prescribed to the then-28-year-aged as early as 2006 due to “various health problems” and a family history of diabetes.
Multiple Athletes Test Positive
Sharapova was not alone in testing positive for the substance. Two Ukrainian biathletes, a Russian cyclist, and a Russian figure skater were among those flagged. However, Sharapova was by far the most successful, wealthy, and professionally established individual among them.
Her explanation that she hadn’t noticed the change to WADA’s prohibited list because she forgot to click a link in an email appeared, to many, amateurish.
A 15-Month Suspension
“Throughout my long career, I have been a very open and honest person and I take full responsibility for the mistakes that I have made,” Sharapova stated. “I have let my fans down, and I’ve let the sport down that I have been playing since the age of four and love.”
She declared her intention to accept the consequences of her actions but insisted she didn’t want her career to complete this way. “I really hope I will be given another chance to play this game.”
The former world number one was initially suspended for two years by the ITF, but the suspension was later reduced to 15 months following an appeal.
Sponsors Abandon Ship
The doping revelation triggered a cascade of sponsor withdrawals. Nike, Porsche, and Swiss watchmaker Tag Heuer – none wanted to be associated with the once-coveted Russian, who stands at 6’2”.
The suspension ended in April 2017, but Sharapova was unable to recapture her former glory in the following years.
In February 2020, the then-33-year-old announced her retirement, not on an ugly carpet in Los Angeles, but in a column for Vanity Fair. She is now a mother, having given birth to a son in July 2022.
The Sharapova case remains a cautionary tale, a stark reminder of the complexities surrounding anti-doping regulations and the immense pressure faced by elite athletes. It’s a story of a superstar’s fall from grace, a stain on an otherwise brilliant career, and a pivotal moment in the history of professional tennis.
